Duality Biologics and GSK enter into an exclusive option agreement to exploit gastrointestinal cancer target, DB-1324 On December 4, 2024, Duality Biologics (“DualityBio”), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (“ADC”) therapeutics, announced an exclusive option agreement with GSK for DualityBio’s ADC candidate,…
